Philadelphia, PA, December 2, 2013 - There is growing concern that long-term untreated posttraumatic stress disorder (PTSD) symptoms may increase the risk of developing a number of medical problems, particularly compromised cardiovascular health.
Heart disease remains the leading cause of death worldwide, according to the World Health Organization. Cardiovascular disease is an umbrella term for diseases of the heart and blood vessels. There are multiple known risk factors, including age, family history, smoking, obesity, high blood pressure, and high cholesterol.
Prior studies show that individuals with PTSD are at increased risk of cardiovascular disease. However, most of these studies proposed this relationship on the basis of self-report measures, creating a need for objective studies to establish the validity of this hypothesis.
In this issue of Biological Psychiatry, Jesse Turner and colleagues at the University of California, San Francisco have done just that and now report new evidence of elevated rates of myocardial ischemia in patients with PTSD.
They recruited 663 outpatients from two Veterans Affairs Medical Centers who underwent a series of assessments, including questionnaires and a blood test to determine their risk factors for cardiovascular disease. Each also completed a structured interview with a clinician, which resulted in a diagnosis of PTSD for 230 of the veterans. Lastly, the participants performed standardized exercise treadmill tests, commonly called 'stress tests', which were used to detect ischemia.
The researchers detected the presence of myocardial ischemia in 17% of the participants with PTSD but only 10% of participants without PTSD. This increase was not explained by differences in traditional cardiac risk factors, health behaviors like alcohol use and sleep quality, or depression.
"Persistent PTSD symptoms produce more than psychological distress; they constitute a major adaptive challenge for the entire body," commented Dr. John Krystal, Editor of Biological Psychiatry. "Increased risk for cardiac ischemia may turn out to be an important new concern for individuals suffering from long-standing untreated PTSD."
"This study adds to a growing literature demonstrating the objective effects of PTSD on the heart. An important next step for this area of research will be to identify the mechanisms through which PTSD may damage the cardiovascular system. Though we controlled for several potential mechanisms, such as traditional cardiovascular disease risk factors, these did not explain the association of PTSD and ischemia," said Dr. Beth Cohen, senior author on the project. "Determining precisely how PTSD can affect the heart will allow us to develop new, tailored treatments to improve the health of veterans and others who experience PTSD."
Considering that up to 30% of veterans suffer from PTSD, this is an important goal. For now, it is increasingly clear that, veteran or not, any individuals suffering from PTSD should seek treatment.
The article is "Objective Evidence of Myocardial Ischemia in Patients with Posttraumatic Stress Disorder" by Jesse H. Turner, Thomas C. Neylan, Nelson B. Schiller, Yongmei Li, and Beth E. Cohen (doi: 10.1016/j.biopsych.2013.07.012). The article appears in Biological Psychiatry, Volume 74, Issue 11 (December 1, 2013), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Beth Cohen at +1 415 221 4810 ext 4851or Beth.Cohen@ucsf.edu.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 135 Psychiatry titles and 13th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2012 Impact Factor score for Biological Psychiatry is 9.247.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Editorial Office Biological Psychiatry
+1 214 648 0880